Clearmind Medicine Inc. (NASDAQ: CMND) announced the completion of treatment and follow-up for 18 participants in its ongoing Phase I/IIa clinical trial of CMND-100 for alcohol use disorder. The company also reported that four additional participants have been treated at its Tel Aviv clinical site.

The FDA-approved trial evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, described as a non-hallucinogenic MEAI-based oral drug candidate, in patients with moderate to severe alcohol use disorder. The multinational, multicenter study is being conducted at Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

"We are very encouraged by the successful completion of treatment and follow-up for these 18 participants, alongside the rapid addition of four more patients at our Tel Aviv center," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

Clearmind describes itself as a clinical-stage biotech company focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics. The company's intellectual property portfolio consists of 19 patent families, including 31 granted patents, according to the press release.

The announcement was made through a company press release. Clearmind shares trade on Nasdaq under the symbol CMND.